FDA Approves Subcutaneous Starting Dose for Leqembi Iqlik, Bringing At-Home Initiation to Early Alzheimer's Treatment
The FDA cleared a subcutaneous starting dose for Eisai and Biogen's Leqembi Iqlik, letting early Alzheimer's patients begin anti-amyloid treatment with a 15-second at-home injection instead of IV infusion.